ENTX
Entera Bio Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$3.11
+1.97%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.15
From 52W high−20.66%
Volume291225.00
Market cap$540.90M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$3.15
From 52W high
−20.66%
Volume
291225.00
Market cap
$540.90M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−37.2x
P/E (TTM)
—
RSI (14)
57.2
MomentumView details →
1D Return
+1.97%
YTD Return
+58.76%
SummaryUpdated Jun 1, 2026
Entera Bio Ltd. (NASDAQ:ENTX) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Jerusalem, Israel. The company went public in June 2018 and specializes in developing oral delivery technologies for large molecule therapeutics, particularly focusing on treatments for bone-related disorders and other unmet medical needs. Entera Bio has established itself as a pioneer in the challenging field of oral delivery of large molecules, which traditionally require injection due to their poor absorption when taken orally.
Similar companies
Latest newsMore news →
Entera Bio Ltd. appointed Laura Hamill as a Class I director effective December 1, 2026, succeeding Yonatan Malca, who departed the board on the same date.30d agoEntera Bio announced plans to start a Phase 3 registrational trial for its oral osteoporosis drug EB613 after reaching agreement with the U.S. FDA on a 12-month placebo-controlled study design.83d ago